DPP4 and obesity disorder: Concerning other DPP-4 inhibitors, Aroor et al. (2013) have demonstrated that linagliptin treatment on ZDF rats for 8 weeks is beneficial in blunting obesity-associated cardiac diastolic dysfunction in the prediabetic state [280].